JESSICA HARKEY: Open Payments
NPI 1295377968 · CORINTH, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,871 in 109 payments from 14 companies in 2025. Trend: 2023 $1,554 · 2024 $2,079 · 2025 $1,871
Food & beverage: $1,871
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 15 | $281 |
| ABBVIE INC. | 22 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $213 |
| Aimmune Therapeutics, Inc. | 12 | $211 |
| Madrigal Pharmaceuticals | 7 | $180 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $163 |
| Celltrion USA Inc. | 11 | $153 |
| QOL Medical, LLC | 6 | $151 |
| GENZYME CORPORATION | 7 | $137 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
Products named: TREMFYA, ENTYVIO, RINVOQ, REZDIFFRA, XIFAXAN, DUPIXENT, VEGZELMA, Sucraid.
Industry payments across MS — which companies pay providers there.
